Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria

ONAN D., ÖKTEM A., YALÇIN B., artiz F.

ASTIM ALLERJI IMMUNOLOJI, vol.17, no.1, pp.41-46, 2019 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.21911/aai.413
  • Journal Name: ASTIM ALLERJI IMMUNOLOJI
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.41-46
  • Keywords: Urticaria, therapeutics, histamine antagonists, Omalizumab, safety, MANAGEMENT, DIAGNOSIS, THERAPY
  • Ankara University Affiliated: Yes

Abstract

Objective: Chronic spontaneous urticaria is a disorder characterized by spontaneous development of pruritic erythematous plaques, angioedema or both. Omalizumab is a recombinant monoclonal antibody that selectively binds to IgE and inhibits its binding to FceRI receptors on mast cells and basophils. We sought to retrospectively assess the efficacy of Omalizumab, the adverse effects due to treatment, and the disease-free duration after treatment in treatment-resistant chronic spontaneous urticaria cases.